CICigna Group

NYSE cigna.com


$ 367.01 $ 2.13 (0.58 %)    

Monday, 16-Sep-2024 15:59:56 EDT
QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 366.85
$ 367.27
$ 366.89 x 200
-- x --
$ 365.62 - $ 370.83
$ 250.89 - $ 370.83
666,844
na
102.55B
$ 0.90
$ 27.66
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-05-2023 03-31-2023 10-Q
7 02-23-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-06-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 10-31-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 02-28-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-cigna-maintains-400-price-target

Cantor Fitzgerald analyst Sarah James reiterates Cigna (NYSE:CI) with a Overweight and maintains $400 price target.

 unitedhealth-follows-competitors-replaces-humira-with-lower-cost-biosimilars

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amge...

 cantor-fitzgerald-reiterates-overweight-on-cigna-maintains-400-price-target

Cantor Fitzgerald analyst Sarah James reiterates Cigna (NYSE:CI) with a Overweight and maintains $400 price target.

 rbc-capital-reiterates-outperform-on-cigna-maintains-384-price-target

RBC Capital analyst Ben Hendrix reiterates Cigna (NYSE:CI) with a Outperform and maintains $384 price target.

 jp-morgan-maintains-overweight-on-cigna-raises-price-target-to-438

JP Morgan analyst Lisa Gill maintains Cigna (NYSE:CI) with a Overweight and raises the price target from $435 to $438.

 expert-ratings-for-cigna
Expert Ratings For Cigna
08/19/2024 16:00:16

 cantor-fitzgerald-reiterates-overweight-on-cigna-maintains-400-price-target

Cantor Fitzgerald analyst Sarah James reiterates Cigna (NYSE:CI) with a Overweight and maintains $400 price target.

 stephens--co-reiterates-overweight-on-cigna-group-maintains-410-price-target

Stephens & Co. analyst Scott Fidel reiterates Cigna Group (NYSE:CI) with a Overweight and maintains $410 price target.

 barclays-maintains-overweight-on-cigna-group-raises-price-target-to-405

Barclays analyst Andrew Mok maintains Cigna Group (NYSE:CI) with a Overweight and raises the price target from $393 to $405.

 us-stocks-tumble-on-economic-geopolitical-concerns-small-caps-chipmakers-sink-meta-rallies-whats-driving-markets-thursday

Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively imp...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION